SU6668
Term · Oncology and biomedicine · MLC-T-ONC-008355
A substance being studied in the treatment of cancer. SU6668 blocks proteins involved in the growth and spread of cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called orantinib and SU006668.
| Identifier | MLC-T-ONC-008355 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | orantinib |
| Synonyms | SU006668 |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-008355",
"term": "SU6668",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of cancer. SU6668 blocks proteins involved in the growth and spread of cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called orantinib and SU006668.",
"expansions": [
"orantinib"
],
"synonyms": [
"SU006668"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/su6668/"
}
Record 15,740 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.